Mazdutide

Study · 2026

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial

Importance Obesity is a worldwide problem and a major public health issue in China. Objective To evaluate the efficacy and safety of mazdutide (a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist) in Chinese adults with obesity (defined as a body mass index of ≥30).

review · 2026

GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists

Adolescent obesity is an escalating global health concern associated with increased risks of cardiovascular disease, type 2 diabetes mellitus, and long-term metabolic complications.

Study · 2026

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary

Study · 2026

Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes

review · 2026

Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes

Introduction Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes.

rct · 2026

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial

Background Once-weekly dual glucagon and glucagon-like peptide-1 receptor agonist mazdutide, administered at 4 and 6 mg, provides substantial weight loss in Chinese adults with overweight or obesity. This trial aimed to evaluate the efficacy and safety of mazdutide 9 mg in Chinese adults with obesity.